Celprot

Quick links to important sections

Celprot

Method of action: Immunosuppressive

Treatment option: Kidney Transplant

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celprot

Celprot is a prescription-only medicine used to prevent the body's immune system response from rejecting a transplanted organ. It is an antirejection medicine used in patients who have received a kidney, heart, or liver transplant.


Property Description
Active ingredient Mycophenolic Acid (MPA)
Form Oral tablets / Capsules, Intravenous injection
Pharmacological class Immunosuppressant Agent / Antimetabolite
Common use Prophylaxis of Organ Rejection
Origin Derived from a Natural Product (fungal metabolite)

Celprot: Defining the Immunosuppressant Agent

Celprot is an Immunosuppressant Agent that works to manage the activity of the body’s natural defenses after a transplant. The medicine belongs specifically to the Antimetabolite Immunosuppressant pharmacological class, a category clinically recognized for its ability to interfere with metabolic pathways critical to immune cell growth.

The active substance is Mycophenolic Acid (MPA), which is central to its therapeutic function. This single active ingredient product is typically administered as a component of a combination therapy, alongside other specialized drugs, to achieve the necessary degree of prophylaxis of organ rejection. Its specialized classification reflects its targeted action on specific immune cells rather than a broad suppression of all defenses.

Composition, Class, and Available Forms

The active ingredient, Mycophenolic Acid (MPA), is delivered in multiple dosage form(s), primarily oral tablets and preparations for intravenous injection. The core substance, MPA, is derived from a natural product, initially identified as a secondary metabolite of Penicillium fungi species. The oral forms are often specially coated to ensure optimal absorption in the body.

Celprot provides the essential MPA moiety, which is the same therapeutically active component produced when the prodrug Mycophenolate Mofetil is processed by the body. This reinforces its identity as a critical immunosuppressive component regardless of the specific salt or derivative used.

How Does Mycophenolic Acid Work at a High Level?

Celprot acts by imposing a controlled slowdown on the multiplication of the specific immune cells responsible for rejection, primarily T and B lymphocytes. It does this by inhibiting the enzyme Inosine Monophosphate Dehydrogenase (IMPDH), a process essential for their rapid growth and proliferation.

This highly selective mechanism of effect focuses the suppression on the immune components that drive the transplant rejection response. The overarching general purpose is to reduce the risk of graft loss by helping the body accept the transplanted organ without incurring non-selective toxicity to other body systems.

Regulatory References

  1. NIH Drug Information Portal (Mycophenolate Mofetil)

What side effects are possible with Celprot?

Possible Side Effects and Safety Information

Celprot (Mycophenolic Acid) is classified by regulatory authorities as an immunosuppressant agent whose safety profile is defined by risks of infection, malignancy, and specific systemic adverse reactions. Safety classifications for adverse reactions are based on official government regulatory documents.

Very Common (ge 10% of patients) reactions include systemic Infections (bacterial, viral, fungal), Leukopenia (low white blood cell count), Anemia, and Diarrhea. Common reactions include Thrombocytopenia (low platelet count), Nausea, Vomiting, and Hypertension.

Serious Adverse Reactions

The most significant safety concerns documented in regulatory warnings are:

  • Embryo-Fetal Toxicity: Celprot is a potent human teratogen, associated with a high risk of Spontaneous Abortion and Congenital Malformations (e.g., ear, face, heart anomalies) when used during pregnancy.
  • Malignancies: The risk of developing Lymphoma and other cancers, especially Skin Cancer, is increased due to long-term immunosuppression.
  • Serious Infections: Increased susceptibility to Opportunistic Infections and viral reactivations (e.g., CMV, BK virus), which can lead to fatal outcomes or organ failure.
  • Progressive Multifocal Leukoencephalopathy (PML): A rare, severe, and potentially fatal viral infection of the brain has been documented.

Population-Specific and High-Level Constraints

Celprot is Contraindicated in pregnant women, women of childbearing potential not using effective contraception, and nursing mothers. Use must also be avoided in patients with rare hereditary deficiencies, such as Lesch-Nyhan syndrome. The official label requires that Live Attenuated Vaccines be avoided and advises limiting Sunlight and UV Exposure due to the associated skin cancer risk.

Overdose and Emergency Response

Celprot (Mycophenolic Acid) overdose is officially documented to present as a severe exacerbation of its known effects, primarily impacting the gastrointestinal and hematological systems. Clinical manifestations include severe nausea, vomiting, and persistent diarrhea, alongside laboratory evidence of bone marrow suppression, potentially resulting in leukopenia or neutropenia. Overexposure carries the serious risk of gastrointestinal hemorrhage and severe, protracted myelosuppression.

In the event of suspected overdose, official guidance mandates that patients or caregivers seek immediate medical attention and contact emergency services without delay. Management is based on providing necessary symptomatic and supportive treatment. Regulators explicitly state that no specific antidote for Mycophenolic Acid is known. Procedural measures may involve administering activated charcoal for gastrointestinal decontamination. However, due to the drug’s high level of protein binding, hemodialysis is officially documented as ineffective for removing the active substance. Following exposure, hospital monitoring is required, including close monitoring of complete blood counts to assess and manage hematological complications.

Therapeutic Uses of Celprot

What Celprot Treats: Main Uses and Benefits

This antirejection therapy is commonly used in situations involving certain distressing symptoms that arise after an organ transplant, primarily for the prophylaxis of organ rejection.

This therapy is applied in clinical settings that involve acute or unstable symptom patterns that can lead to functional strain on the transplanted kidney, heart, or liver. This medicine is considered relevant in conditions involving episodic or fluctuating manifestations that affect the transplanted organs. Celprot is commonly used to help with maintaining a sense of stability following transplantation, helping to address symptom clusters that may become intense or disruptive.

“The medication assists with maintaining functional stability when symptoms are more noticeable, providing supportive symptom management.”

By supporting the body during this critical period, Celprot provides support that contributes to easing the overall symptom load and helps patients cope more steadily during periods of heightened discomfort.

Quick Fact: Support for Organ-Specific Functional Stress
This antirejection medicine plays a role in managing symptoms related to sudden or progressive organ-specific functional stress that can arise when functional stability is affected.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Celprot

Celprot is subject to strict eligibility rules as defined in official regulatory labeling to minimize risks, primarily its potential for causing fetal harm.

Contraindications (Must Not Use)

Population Group Reason Status
Pregnant Females Known high risk of miscarriage and severe birth defects (teratogenicity). Absolute Contraindication
Breastfeeding Mothers Potential for serious adverse effects in the nursing infant. Absolute Contraindication
Hypersensitivity Known allergy to Celprot or its components. Absolute Contraindication
Rare Metabolic Disorders Patients with inherited enzyme deficiencies like Lesch-Nyhan syndrome. Contraindication

Age-Related Eligibility

Celprot is typically approved for use in adults and pediatric recipients of allogeneic kidney, heart, or liver transplants starting at 3 months of age. Use in infants younger than 3 months is generally not established due to insufficient data.

Condition- and Organ-Specific Restrictions

Patients with severe chronic renal impairment (outside of the immediate post-transplant period) and those with hepatic impairment require special consideration and often have specific dose limitations or require additional monitoring. Eligibility is also conditional on mandatory use of highly effective contraception for females of reproductive potential (during and for at least six weeks after stopping treatment) and for male patients with female partners of childbearing potential (during and for at least 90 days after stopping).

What should I know about interactions with other medicines?

Celprot Interactions with Other Medicines and Products

Celprot’s official interaction profile is characterized by interactions that can significantly alter its concentration in the body or increase the risk of specific adverse effects when co-administered with other agents.

Pharmacokinetic and Pharmacodynamic Domains

Interaction Type Practical Implication (Based on Regulatory Labeling)
Exposure-Altering Co-administration Substances known to significantly reduce Celprot's exposure (e.g., Cholestyramine, certain Antacids, or St. John's Wort) may require timing separation or avoidance. Strong inhibitors of Celprot's elimination pathways may lead to increased plasma levels.
Pharmacodynamic Risk Aggregation Combinations with other agents that carry risks for myelosuppression (e.g., other immunosuppressants) or gastrointestinal complications (e.g., NSAIDs) necessitate heightened clinical awareness.
Counteracting Therapeutic Agents Celprot is documented to reduce the effectiveness of oral hormonal contraceptives, requiring patients to use alternative or additional barrier methods.

Official Regulatory Restrictions

The co-administration of Celprot with live attenuated vaccines is restricted due to the potential for serious infection. Drugs that compete for renal tubular secretion (e.g., Acyclovir) can increase Celprot's concentration and require monitoring. Specific dosage timing is required to separate Celprot from drugs that interfere with its absorption, such as antacids containing aluminum and magnesium.

Mechanism of Action

How Celprot Works

Celprot operates by exerting a targeted, modulating effect on specific biological signaling pathways. Its mechanism involves a sequence of precise actions that commence at the cellular level.

Selective Receptor Modulation and Signal Initiation

Celprot acts primarily by binding to and modulating the activity of the R A receptor system . This selective interaction initiates the drug's effect by immediately dampening the signal input, which targets receptor activation characteristic of heightened signaling.

Interference with Downstream Signaling Cascades

Following receptor interaction, Celprot's effect flows downstream to interfere with the P SG signal transduction cascades . This action results in the limitation of key intracellular messengers, thereby modifying early molecular steps that would otherwise escalate into a heightened cellular response.

Adjustment of Regulatory Pathway Activity

By adjusting the flow of information through the R A and P SG pathways, Celprot engages mechanisms that influence intrinsic feedback loops within targeted pathways. This mechanistic dampening leads to an adjustment in the activity of targeted physiological responses, resulting in physiological adjustments that align with the drug's mechanistic effects.

Dosage and Administration Information

Official Administration Guidelines for Celprot

Celprot must be used exactly as prescribed by a transplant specialist. Official guidelines specify precise rules for administration, preparation, and managing missed doses, which are outlined below.


Administration Scope

Instruction Domain Official Requirement (Example Placeholder)
Route of Administration Oral (tablet or capsule form) or Intravenous (IV) infusion.
Dosing Schedule Administered twice daily (BID), with the specific dose determined by the transplanted organ (e.g., 1 g BID for kidney, 1.5 g BID for heart/liver).
Timing in Relation to Meals Recommended to be taken on an empty stomach. For stable transplant patients, it may be administered with food if necessary.
Preparation Requirements Tablets and capsules must be swallowed whole; they must not be crushed, opened, or chewed.
Age-Group Administration Not recommended for patients under 18 years of age (in certain contexts, or based on the lack of safety data). Pediatric dosing for kidney transplant is 600 mg/ m^2 orally twice daily, up to 2 g daily.
Missed-Dose Rules If a dose is missed, take it as soon as remembered, unless it is closer than 2 hours to the next scheduled dose, in which case the missed dose should be skipped.
Special Procedural Conditions Intravenous infusion must be administered slowly over a period of no less than 2 hours.

Procedural Structure Summary

The official instructions mandate a twice-daily frequency and an Oral or IV administration method. The protocol emphasizes the critical need to administer the drug without altering its form (swallowing tablets whole) and details specific timing requirements regarding food to standardize exposure. This strict procedural framework ensures the dose is delivered and maintained consistently according to established parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Celprot

The clinical research for Celprot in kidney transplantation has included large, prospective Randomized Controlled Trials (RCTs). These studies typically compared Celprot, used alongside other specialized medicines, against established treatment regimens, such as those containing Azathioprine. Research examined outcomes related to physical discomfort and systemic imbalance by tracking the frequency of biopsy-proven acute rejection (BPAR), an outcome used to evaluate the immune system's response to the transplanted organ.

Other important study outcomes measured the overall function of the transplanted kidney over time, using measurements like serum creatinine and estimated filtration rates. Findings describe patterns observed in these studies where Celprot-based regimens were associated with measured patterns that were distinct from the established treatment regimens. However, results apply only to the specific populations studied, and certainty remains low regarding the very long-term outcomes and the durability of the medication's effect beyond the time frame of the original trials.


Evidence for Use in Liver and Heart Transplantation

Celprot was evaluated in liver transplantation through comparative clinical studies and cohort studies, tracking the frequency of acute rejection episodes and measuring survival rates for the graft and the patient. Similarly, research examined the use of Celprot in heart transplantation patients, primarily tracking the prevention of acute rejection and monitoring long-term measurements of patient and graft survival.

Evidence for Celprot in heart transplant recipients relies on scientific principles and extrapolation from trials conducted in other solid organ transplant settings (like kidney and liver). The volume of large, pivotal RCTs specifically for heart transplantation is more limited than that for kidney transplantation, contributing to uncertainty in some specific long-term scenarios.


Evidence Gaps and Special Populations

Celprot was evaluated in patient groups beyond the general adult population, particularly pediatric recipients. For these young patients, the evidence for its use often comes from scientific principles relating drug exposure in the body (pharmacokinetics) in children and the patterns observed in adult and pediatric kidney studies.

Data for certain long-term maintenance protocols and specific immunosuppressive combinations remain insufficient. Research is ongoing to determine the most effective ways to monitor the drug’s activity for all patients, as individual responses may vary widely.

Key Studies & References

  1. Mycophenolate Mofetil in pediatric renal transplant recipients (Systematic Review or Guideline supporting pediatric use)

Frequently Asked Questions (FAQ)

Common questions about Celprot (FAQ)


Q: How quickly does Celprot start working after you take it?

According to the official product information on drug absorption, the active substance, Mycophenolic Acid (MPA), is typically absorbed rapidly after an oral dose. It generally reaches its maximum concentration in the bloodstream within 0.5 to 1.5 hours. This absorption profile is a factor in how the medication is managed.


Q: Is Celprot known to cause weight gain?

Weight gain itself is not consistently listed as one of the most common or very common side effects reported in the official clinical trial data. However, regulatory documents do sometimes report changes in metabolism, such as high blood sugar or high cholesterol, and fluid retention (edema) as possible findings.


Q: How long can I expect the effects of Celprot to last?

The half-life of the active substance, Mycophenolic Acid, is generally reported to be between 8 and 18 hours. This time frame represents how long it takes for the concentration of the drug in your body to be reduced by half. The twice-daily dosing schedule is intended to help maintain consistent levels of the active substance in the body.


Q: Is it normal to feel a bit drowsy after taking Celprot?

Dizziness is listed as a potential adverse reaction in the nervous system category of official regulatory documents. Due to the possibility of dizziness, official information may include general cautionary statements regarding activities that require full alertness.


Q: Can Celprot cause problems with your stomach lining?

Yes, official regulatory warnings indicate that Celprot is associated with an increased risk of serious gastrointestinal complications. These may include stomach bleeding (hemorrhage), ulceration, and perforation of the stomach or bowel lining. A history of stomach or bowel problems is a factor that medical specialists must consider, as outlined in the official warnings.


Q: Can Celprot cause changes in mood or anxiety?

Official reports from clinical trials include anxiety as a potential adverse reaction within the psychiatric disorders category. Patients experiencing changes in mood or anxiety are typically advised to discuss these with their transplant or healthcare specialist.


Q: How long does it typically take for Celprot to clear the system completely?

The half-life of the active drug in the blood is between 8 to 18 hours, depending on the specific formulation. Given this, it usually takes several half-lives for any medication to be almost entirely cleared from the body.


Q: What are the signs that Celprot is actually working for my condition?

The main goal of this medication is the prevention of acute organ rejection. Your specialist monitors its success using clinical measures, such as tracking the frequency of rejection episodes and testing the function of the transplanted organ, for example, by measuring serum creatinine levels.


Q: What are the most common reasons someone would stop taking Celprot?

Official regulatory information on clinical studies indicates that the most common reasons patients discontinue the drug are due to adverse reactions. These frequently include blood disorders (such as low white blood cell counts) and gastrointestinal issues like severe diarrhea or nausea.


Q: Is there a rebound effect if you suddenly stop taking Celprot?

Regulatory documents state that missing doses or discontinuing the drug increases the risk that the immune system will reject the transplanted organ. The drug is essential for helping the body accept the transplanted organ.


Q: Does taking Celprot affect blood test results?

Yes, taking Celprot can cause changes in your blood cell counts. These potential effects include leukopenia (low white blood cells), anemia (low red blood cells), and thrombocytopenia (low platelets). For this reason, blood count monitoring is typically required as part of the treatment protocol.


Q: Are there known allergic reactions to the inactive ingredients in Celprot?

Yes, official regulatory documents state that Celprot is strictly contraindicated if a patient has a known allergy or hypersensitivity not just to the active substance, but also to any of the inactive ingredients used in the product.


Q: Does Celprot carry a risk of dependence or addiction?

No. Official regulatory classification confirms that Celprot is not a controlled substance and is not listed under any schedule for potential abuse or dependence.


Q: Is the efficacy of Celprot reduced over time?

Clinical trials generally establish the efficacy of the drug over an initial period, such as one year. While the treatment is continuous, regulatory documents note that certainty regarding very long-term outcomes and the durability of the medication's effect beyond the trial period is generally low.


Q: Is it okay to switch the time of day I take Celprot?

The medication is prescribed to be taken twice daily, which requires the doses to be spaced approximately 12 hours apart to ensure consistent drug levels in the blood. Regulatory documents emphasize that any potential changes to the dosing schedule should be managed under the guidance of the prescribing specialist.


Q: Is Celprot more effective for acute issues or chronic management?

According to the official indication, the drug is prescribed for the prophylaxis of organ rejection. Prophylaxis means prevention, which establishes the drug's primary role as a long-term, chronic management tool following transplant surgery.


Q: Can Celprot be taken if you have diabetes?

Official reports of adverse reactions list diabetes mellitus and hyperglycemia (high blood sugar) as potential findings in the Metabolism and Nutrition Disorders section. In official regulatory information, patients with pre-existing diabetes or those who experience high blood sugar are identified as requiring additional specialist oversight.


Q: What is the standard length of treatment course for Celprot?

As part of an anti-rejection combination therapy, Celprot is typically indicated for the continuous, long-term management of the immune response. The treatment is designed to be continuous for the long-term management of the transplanted organ.


Q: Are there different strengths available for Celprot tablets?

Yes. The regulatory documents on dosage forms and strengths confirm that the active ingredient is available in multiple forms, including oral tablets, often in different milligram strengths.

How should Celprot be stored and disposed of?

Celprot must be stored and handled according to specific conditions mandated by regulatory labeling to maintain its efficacy.

Required Storage Conditions

The medicine must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). It is a mandatory requirement to not freeze Celprot and to protect it from light and excessive moisture. The product should remain in its original container and be kept tightly closed.

For child safety, Celprot must be stored out of the reach and sight of children.

Official Disposal Instructions

Unused or expired Celprot should be disposed of via a regulated drug take-back program. If a take-back program is not available, the medicine must be mixed with an undesirable substance (such as dirt) and placed in a sealed container before discarding in household trash. It is explicitly prohibited to flush the product down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Celprot found in:

A-Z Index: